Syros Pharmaceuticals, Inc. Syros Pharmaceuticals, Inc.
  • Home
  • Our Coordinated Expression
    • Overview
    • Our Culture, Mission & Values
    • Our Commitment to Diversity, Equity & Inclusion
    • Message from BIO
  • Our People
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Tamibarotene
    • SY-2101
    • SY-5609
    • Expanded Access Policy
  • Clinical Trials
  • Platform
    • Overview
    • What is Gene Control?
    • Publications and Abstracts
  • Patients
  • Investors & Media
  • Partners
  • Careers
  • Blog
  • Contact
Investors & Media

Investors & Media

  • Overview
  • News
    • Email Alerts
    • Press Releases
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Company Info
    • Profile
    • Leadership
    • Contacts
    • Analyst Coverage
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Annual Reports
    • IRS Tax Form 8937
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Filings
    • Quarterly Reports
    • Proxy
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor & Media Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

Press Releases

  • News

  • Email Alerts
  • Press Releases
Mar 4, 2021

Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Feb 25, 2021

Syros to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 4, 2021

Feb 22, 2021

Syros to Participate in Upcoming Investor Conferences in March

Jan 19, 2021

Syros Announces Pricing of $75.6 Million Public Offering of Common Stock

Jan 19, 2021

Syros Announces Proposed Offering of Common Stock

Jan 11, 2021

Syros Announces Strategic Priorities and Expected Milestones

Jan 7, 2021

Syros to Present at 39th Annual J.P. Morgan Healthcare Conference

Dec 8, 2020

Syros Closes $90.5 Million Strategic Financing

Dec 5, 2020

Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies

Dec 5, 2020

Syros Presents New Data From Phase 2 Clinical Trial of SY-1425 and Announces Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML

RSS
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...27
    © 2023 Syros Pharmaceuticals, Inc. All Rights Reserved.
    Privacy Policy Terms of Use Sitemap
    twitter logo linkedin logo